Showing results (121-130 of 147) with videos related to
Sort By:
Pageof 15
Gynecologic Oncology|August 28, 2021
DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivoJoan Tymon-Rosario, Elena Bonazzoli, Stefania Bellone, et al.Gynecologic Oncology|May 22, 2022
Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitorJoan R Tymon-Rosario, Paola Manara, Diego D Manavella, et al.The Lancet. Oncology|April 6, 2019
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trialKathleen N Moore, Angeles Alvarez Secord, Melissa A Geller, et al.Gynecologic Oncology|December 17, 2019
In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinomaChanhee Han, Emanuele Perrone, Burak Zeybek, et al.International Journal of Cancer|June 11, 2015
Clostridium perfringens enterotoxin C-terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy-resistant ovarian cancerEmiliano Cocco, Erik M Shapiro, Sara Gasparrini, et al.Oncotarget|February 22, 2020
Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomasSalvatore Lopez, Emanuele Perrone, Stefania Bellone, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2020
Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival AnalysisAmanda N Fader, Dana M Roque, Eric Siegel, et al.Molecular Cancer Therapeutics|September 7, 2023
In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous CarcinomaLevent Mutlu, Diego D Manavella, Stefania Bellone, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2018
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neuAmanda N Fader, Dana M Roque, Eric Siegel, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2018
Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial CancerElena Bonazzoli, Federica Predolini, Emiliano Cocco, et al.Pageof 15